Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin (IL)-4/IL-13, key and central drivers of type 2 inflammation in multiple diseases including EoE.13, 14, 15 LIBERTY EoE TREET was a 3-part, double-blind, placebo-controlled, phase 3 study that demonstrated improvements in histologic, symptomatic, endoscopic, and molecular aspects of the disease in adults and adolescents with EoE treated with dupilumab up to 52 weeks.16 This evidence concerns the gene IL13 and eosinophilic esophagitis.